Can GlaxoSmithKline plc’s Share Price Return To 2,000p?

Will GlaxoSmithKline plc (LON: GSK) be able to return to its previous highs?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m looking at some of the most popular companies in the FTSE 100 to try and establish whether or not they have the potential to return to historic highs. 

Today I’m looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) to ascertain if its share price can return to 2,000p.

Initial catalyst

Of course, to establish whether or not the Glaxo’s share price will push back up to 2,000p, we need to establish what caused it to move there in the first place. In the case of Glaxo, it would appear that this rally was spurred by the merger of Glaxo with SmithKline Beecham back in 2001, forming the worlds largest pharmaceutical company.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

What’s more, at this time the market was seemingly won over by the newly combined, GlaxoSmithKline’s future growth prospects. Indeed, investors were right to believe that the company was set for growth, as over the space of the next year, Glaxo’s pre-tax profit exploded 15% and earnings per share rose 10%.

Still, this growth was not enough to offset wider market consensus and unfortunately, just before Glaxo reached its high, the tech bubble had started to deflate. Over the next year-and-a-half, Glaxo’s share price declined a shocking 45%, roughly in line with similar declines reported for the FTSE 100.

But can Glaxo return to its former glory?

Sadly, Glaxo has been struggling during the past few years as it has lost the exclusive manufacturing rights to a number of its treatments and earnings have started to slide.

That said, it would appear that this is only reason that is standing in the way of the company’s return to greatness. Indeed, the company is already primed for a return to 2,000p per share, if it can increase margins and drive profits back to the levels seen during 2002.

Specifically, during 2002, Glaxo generated profits of £6.5 billion on revenues of £20.5 billion. However, during 2012, Glaxo reported revenues of £26.5 billion but profits of only £4.9 billion.

Of course, this depends on the development of the company’s treatment pipeline. Still, I have confidence in Glaxo’s ability to ride out this short-term slide in sales.

Actually, my figures suggest that if Glaxo does manage to drive profitability back to the level seen during 2002, the company is likely to be worth significantly more than 2,000p per share. In particular, during the past ten years, Glaxo has reduced its number of shares in issue by around 20%. This implies that if Glaxo’s profits hit £6.5 billion again, the company will earn 133p per share.

All in all, this implies that Glaxo will trade at a P/E of only 12.5 based on its current price. Moreover, it is likely that the market will place a premium on this kind of earnings growth.

Foolish summary

So, it would appear that Glaxo has all the foundations in place to make another run at 2,000p. The company just needs to cut costs further and inject some life into its treatment portfolio.

Overall, I feel that GlaxoSmithKline’s share price can return to 2,000p. 

Is this a top choice for growing wealth now?

Before deciding, we think this pick is another must-see.

Discover ‘One Top Growth Stock from The Motley Fool’ absolutely FREE.

Though past performance does not guarantee future results, over the past 5 years, it’s seen consistent double-digit revenue growth. ‘Return on capital’ - a key measure of business quality - is a colossal 57%. That’s almost 6 times higher than the UK average!

Best of all, it has a cult-like following. Customers who’re raving fans, potentially spending more money, more often - whatever the economy.

In our experience, discoveries like this are extremely rare.

So please, don’t leave without seeing, ‘One Top Growth Stock from The Motley Fool’, which includes both the Risks and opportunities.

Claim your FREE copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned in this article. The Motley Fool has recommend shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

3 world-class stocks to consider buying, while they’re ‘on sale’

Looking for stocks to buy? These three all have attractive long-term prospects and are currently trading 20% or more below…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Could BP’s share price rebound over the next 12 months? These analysts think the answer is ‘yes’!

BPs share price has plummeted over the last year. But City brokers think things are about to turn around, as…

Read more »

Investing Articles

Is this an unmissable opportunity to buy Nvidia stock?

Nvidia stock is down 33% from its peak, driven by tariffs and geopolitical pressures. Despite this, some investors may spy…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Dividend investors! Here’s what Warren Buffett says builds wealth in the stock market

Reinvesting dividends at yields of 8% or higher looks like a good way of building wealth. But Warren Buffett has…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s my Stocks and Shares ISA plan for 2025-26

A Stocks and Shares ISA helps investors avoid taxes on dividends and capital gains. And Stephen Wright has a plan…

Read more »

Dividend Shares

Of the 20 highest-yielding FTSE 100 stocks, this is my top pick

This FTSE 100 stock currently offers a yield of 6.4%. But Edward Sheldon believes it’s capable of providing share price…

Read more »

Investing Articles

Could Tesla’s share price jump over the next 12 months? These analysts think so!

Tesla's share price has fallen by almost a third since 1 January. But optimism is high that Elon Musk's company…

Read more »

Investing Articles

I asked ChatGPT where the FTSE 100 will be in 6 months: here’s what it said…

Let’s be realistic, ChatGPT can’t predict the future. But it did do a good job of compiling data from brokerages…

Read more »